Schroder Investment Management Group Grows Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Schroder Investment Management Group raised its stake in IDEXX by 2.4% in Q3 to 323,305 shares, worth about $203.86 million and representing roughly 0.40% of the company.
• Company insiders have been net sellers: insiders disposed of 45,957 shares (~$29.86 million) in the last quarter, including EVP Michael G. Erickson (5,371 shares) and EVP Nimrata Hunt (1,758 shares).
• Equity analysts maintain a consensus of "Moderate Buy" with an average price target of $783.33, while IDEXX set FY2026 guidance of $14.290–$14.800 EPS (analysts expect ~11.93 EPS for the current year).

Schroder Investment Management Group increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 323,305 shares of the company's stock after acquiring an additional 7,520 shares during the quarter. Schroder Investment Management Group owned about 0.40% of IDEXX Laboratories worth $203,863,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of IDXX. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth $30,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories during the third quarter valued at about $31,000. Armstrong Advisory Group Inc. increased its holdings in shares of IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock worth $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in shares of IDEXX Laboratories in the third quarter worth about $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new stake in shares of IDEXX Laboratories in the third quarter worth about $35,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on IDXX shares. Barclays cut their price target on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Weiss Ratings cut IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, January 29th. UBS Group cut their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a report on Tuesday, February 3rd. BTIG Research reduced their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research report on Tuesday, February 3rd. Finally, Piper Sandler lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research report on Monday, February 9th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $783.33.

Insiders Place Their Bets

In other news, EVP Michael G. Erickson sold 5,371 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares of the company's stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $610.45 on Tuesday. The stock has a market cap of $48.60 billion, a price-to-earnings ratio of 46.71, a price-to-earnings-growth ratio of 3.69 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock has a 50 day moving average price of $665.39 and a 200-day moving average price of $668.46. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business's quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.